Baylor College of Medicine

Twinss Study on patients with Sjögren's Syndrome (H-46154)

Description

Content

Novartis ccfz533b2201 a 48-week, 6-arm, randomized, double-blind, placebo controlled multicenter trial to assess the safety and efficacy of multiple cfz533 doses administered subcutaneously in two distinct populations of patients with Sjögren's Syndrome (Twinss)

IRB: H-46154

Status:

Active

Created:

Back to topback-to-top